Pictet Asset Management SA cut its stake in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 0.4% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 17,555 shares of the biotechnology company’s stock after selling 70 shares during the period. Pictet Asset Management SA’s holdings in Repligen were worth $2,956,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of RGEN. PNC Financial Services Group Inc. increased its holdings in shares of Repligen by 6.2% during the first quarter. PNC Financial Services Group Inc. now owns 5,723 shares of the biotechnology company’s stock worth $1,077,000 after buying an additional 333 shares in the last quarter. Great West Life Assurance Co. Can increased its holdings in shares of Repligen by 8.2% during the first quarter. Great West Life Assurance Co. Can now owns 28,126 shares of the biotechnology company’s stock worth $5,427,000 after buying an additional 2,143 shares in the last quarter. Raymond James Trust N.A. increased its holdings in shares of Repligen by 37.4% during the first quarter. Raymond James Trust N.A. now owns 2,331 shares of the biotechnology company’s stock worth $438,000 after buying an additional 634 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in Repligen by 5.1% in the first quarter. Dimensional Fund Advisors LP now owns 229,785 shares of the biotechnology company’s stock valued at $43,221,000 after purchasing an additional 11,121 shares during the period. Finally, Sei Investments Co. increased its holdings in Repligen by 18.5% in the first quarter. Sei Investments Co. now owns 59,917 shares of the biotechnology company’s stock valued at $11,331,000 after purchasing an additional 9,352 shares during the period. 96.28% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of analysts recently weighed in on RGEN shares. Stephens increased their price objective on Repligen from $180.00 to $200.00 and gave the company an “overweight” rating in a report on Thursday, August 3rd. Stifel Nicolaus decreased their price objective on Repligen from $210.00 to $200.00 in a report on Wednesday, June 28th. Deutsche Bank Aktiengesellschaft decreased their price objective on Repligen from $180.00 to $165.00 in a report on Wednesday, May 3rd. Craig Hallum decreased their price objective on Repligen from $207.00 to $200.00 and set a “buy” rating for the company in a report on Thursday, August 3rd. Finally, Royal Bank of Canada increased their price objective on Repligen from $157.00 to $195.00 and gave the company an “outperform” rating in a report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. According to MarketBeat, Repligen currently has an average rating of “Moderate Buy” and a consensus target price of $199.44.
Repligen Price Performance
Shares of Repligen stock opened at $163.17 on Friday. Repligen Co. has a one year low of $134.64 and a one year high of $238.18. The firm has a market capitalization of $9.10 billion, a price-to-earnings ratio of 67.43, a PEG ratio of 3.79 and a beta of 1.01. The business has a 50-day simple moving average of $158.94 and a 200 day simple moving average of $165.77.
Repligen (NASDAQ:RGEN – Get Free Report) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported $0.53 EPS for the quarter, beating analysts’ consensus estimates of $0.49 by $0.04. Repligen had a return on equity of 7.83% and a net margin of 18.92%. The business had revenue of $159.20 million during the quarter, compared to analyst estimates of $165.93 million. During the same period in the previous year, the company posted $0.91 EPS. The firm’s revenue was down 23.3% compared to the same quarter last year. On average, sell-side analysts expect that Repligen Co. will post 1.83 EPS for the current year.
Repligen Profile
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
See Also
- Five stocks we like better than Repligen
- 3 Fintech Stocks With Good 2021 Prospects
- Can These 2 Industrial Titans Extend Double-Digit YTD Growth?
- Breakout Stocks: What They Are and How to Identify Them
- How to Profit from These 3 Membership Club Stocks’ Strengths
- Stock Average Calculator
- 5 Best High-Yield Dividend Stocks for Any Economic Climate
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN – Free Report).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.
